Ticker: TENX

08:09am, Monday, Aug 10, 2026

Tenax Therapeutics Stock Plummets 84% After Phase 3 Trial Failure

Tenax Therapeutics shares crater 84% in pre-market after its Phase 3 LEVEL trial misses key endpoints for TNX-103 in pulmonary hypertension, wiping out recent bullish optimism.